Ivermectin In Treatment of COVID 19 Patients

Study Overview
=================
Brief Summary
-----------------
as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

Detailed Description
-----------------
the study will compare the effect of ivermectin in comaprison and addition to the standard mode of care for the COVID 19 patients

Official Title
-----------------
The Use of Ivermectin In the Treatment of COVID 19 Patients

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Drug: Ivermectin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Asymptomatic mild cases and moderate cases proven to be infected by COVID 19 by viral RNA swap Exclusion Criteria: Contraindications for the drug: hypersensitivity. Any medications with possible drug interactions. Severe cases. Any malignant condition. Pregnant females. Breast feeding females. Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A ivermectin alone<br>ivermectin will be administarted alone to COVID 19 patients | Drug: Ivermectin<br>* use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt<br>* Other names: hydroxychloroquine;|
| Experimental: B standard care alone<br>standard care will be administarted alone | Drug: Ivermectin<br>* use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt<br>* Other names: hydroxychloroquine;|
| Active Comparator: C ivermectin added to standard of care<br>ivermectin will be administarted in adition to standard care | Drug: Ivermectin<br>* use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt<br>* Other names: hydroxychloroquine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to evaluate the role of Ivermectin as a line of treatment for COVID 19 | the role of ivermectin in the cure of COVID 19 patients | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To asses the rate of viral clearance in comparison to other treatment protocols. | to compare the results of ivermectin with the standard care | 2 months |